Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Rein Therapeutics (RNTX) Accumulated Depreciation & Amortization (2016 - 2023)

Rein Therapeutics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $358000.0 for Q4 2023.

  • Quarterly Accumulated Depreciation & Amortization rose 32.59% to $358000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $358000.0 through Dec 2023, up 32.59% year-over-year, with the annual reading at $358000.0 for FY2023, 32.59% up from the prior year.
  • Accumulated Depreciation & Amortization was $358000.0 for Q4 2023 at Rein Therapeutics, up from $295000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $629000.0 in Q3 2020 and troughed at $166000.0 in Q4 2020.
  • The 5-year median for Accumulated Depreciation & Amortization is $270000.0 (2022), against an average of $319764.7.
  • Year-over-year, Accumulated Depreciation & Amortization tumbled 70.42% in 2021 and then soared 35.12% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $522000.0 in 2019, then tumbled by 68.2% to $166000.0 in 2020, then rose by 27.71% to $212000.0 in 2021, then rose by 27.36% to $270000.0 in 2022, then soared by 32.59% to $358000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNTX's Accumulated Depreciation & Amortization are $358000.0 (Q4 2023), $295000.0 (Q3 2023), and $285000.0 (Q2 2023).